Scientists have discovered a potential new treatment for familial hypercholesterolemia, inspired by signs seen in the Mona ...

More than 20 years after the first successful engraftment of human leukocytes and hematopoietic organs in mice, scientists met for the 2nd International Workshop on Humanized Mice to discuss ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Editas Medicine (EDIT) announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of ...

and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic stem cells and liver cells and in vivo delivery data in humanized mice to two additional target cell ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...